Roivant Sciences ( (ROIV) ) just unveiled an update.
Organon has announced plans to acquire Dermavant Sciences Ltd., enhancing its dermatology portfolio with the innovative VTAMA® cream, a non-steroidal treatment approved for plaque psoriasis and under FDA review for atopic dermatitis. The $1.2 billion deal includes upfront and milestone payments plus royalties, aiming to strengthen Organon’s commitment to women’s health by addressing conditions with disproportionate effects on women. This strategic move is expected to leverage Organon’s commercial and medical capabilities to expand VTAMA’s global reach, underscoring Roivant’s collaborative approach to value creation and innovation in healthcare.
For a thorough assessment of ROIV stock, go to TipRanks’ Stock Analysis page.
